10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.

      Cancer control : journal of the Moffitt Cancer Center

      Blood Transfusion, Bone Marrow Transplantation, trends, Europe, epidemiology, Forecasting, Graft vs Host Disease, immunology, therapy, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Humans, Immunotherapy, Adoptive, Leukemia, Lymphocyte Transfusion, standards, Lymphocytes, blood, Medicine in Art, North America, Recurrence, Tissue Donors, Transplantation, Homologous, Treatment Outcome

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Patients with hematologic malignancies in relapse after allogeneic bone marrow transplantation can be treated by infusing leukocytes from the original stem cell donor. The published literature on donor lymphocyte infusion (DLI) was reviewed. DLI induces complete remissions in the majority of patients with chronic myeloid leukemia (CML) in early-stage relapse and in less than 30% of patients with relapsed acute leukemia, myelodysplasia, and multiple myeloma. DLI-induced remissions of chronic phase CML are durable, but as many as half of patients with other diseases ultimately relapse. Complications of DLI include acute and chronic graft-vs-host disease (GVHD) and aplasia, which induce profound immunosuppression and susceptibility to opportunistic infections. There is a strong correlation of GVHD and disease response. Novel methods of augmenting the antitumor efficacy of DLI and of dissociating the graft-vs-leukemia effect from GVHD are needed. These studies will require an improved understanding of the cellular and molecular mechanisms of alloreactivity and the development of novel agents to control the nature and intensity of the alloimmune response.

          Related collections

          Author and article information

          Journal
          11965233

          Comments

          Comment on this article